Cargando…

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zopf, Dieter, Fichtner, Iduna, Bhargava, Ajay, Steinke, Wolfram, Thierauch, Karl‐Heinz, Diefenbach, Konstanze, Wilhelm, Scott, Hafner, Frank‐Thorsten, Gerisch, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119973/ https://www.ncbi.nlm.nih.gov/pubmed/27734608 http://dx.doi.org/10.1002/cam4.883

Ejemplares similares

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
por: Gerisch, Michael, et al.
Publicado: (2017)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
por: Daudigeos-Dubus, Estelle, et al.
Publicado: (2015)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
por: Huynh, Hung, et al.
Publicado: (2015)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
por: Shigeta, Kohei, et al.
Publicado: (2020)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
por: Doleschel, Dennis, et al.
Publicado: (2021)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens
por: Cao, Fei, et al.
Publicado: (2021)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
por: Tsai, Tung-Hu, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
por: Fondevila, Flavia, et al.
Publicado: (2019)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I
por: Ellinghaus, Peter, et al.
Publicado: (2013)

Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers
por: Rolff, Jana, et al.
Publicado: (2009)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Investigating the replicability of preclinical cancer biology
por: Errington, Timothy M, et al.
Publicado: (2021)

Effects of chronic low‐dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis
por: Rohwer, Nadine, et al.
Publicado: (2020)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

Is preclinical research in cancer biology reproducible enough?
por: Kane, Patrick Bodilly, et al.
Publicado: (2021)

Challenges for assessing replicability in preclinical cancer biology
por: Errington, Timothy M, et al.
Publicado: (2021)

Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
por: Keunecke, Anne, et al.
Publicado: (2020)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

Preclinical murine tumor models: A structural and functional perspective
por: Guerin, Marion V, et al.
Publicado: (2020)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u51u6isp1uuo6jdgq8qc2rc8nq